The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
BUSINESS Japan Ethical Drug Sales Zoom 12.1% in February: Crecon
April 8, 2024
-
BUSINESS Keytruda Tops Japan Sales List for 6th Month in March: Encise
April 8, 2024
-
BUSINESS Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
-
REGULATORY MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
April 5, 2024
-
BUSINESS Rohto, Mitsui to Buy Singapore’s Chinese Medicine Firm for SGD800 Million
April 5, 2024
-
BUSINESS Nippon Shinyaku, MiNA Therapeutics Join Hands in Rare CNS Disorders
April 5, 2024
-
BUSINESS Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
-
REGULATORY Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
-
BUSINESS Tarlige Winner in February GP Rep Promotion Rankings
April 4, 2024
-
BUSINESS Taisho’s Positive PIII Data Set Stage for Japan Filing of Insomnia Med
April 4, 2024
-
BUSINESS FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024
-
BUSINESS Chugai Offers 5% Pay Raise in 30-Year-Old Model Case
April 4, 2024
-
BUSINESS Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
-
BUSINESS Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria
April 4, 2024
-
BUSINESS Sawai Closes Sale of US Business to Taiwan CDMO
April 4, 2024
-
ORGANIZATION PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
-
REGULATORY Offset Technology-Driven Cost Rise with Spending Reforms: Govt Economic Estimate
April 3, 2024
-
ORGANIZATION Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
April 3, 2024
-
REGULATORY Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
-
REGULATORY Japan Govt Ends COVID Vaccine Supply as Emergency Program Winds Up
April 3, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…